Status and phase
Conditions
Treatments
About
This study is to compare and evaluate the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab and chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy in chemotherapy-naïve participants with HER2- negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
210 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Ono Pharmaceutical Co., Ltd.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal